| 1 |
31359271 | Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes. | 2020 Jan |
1 |
| 2 |
32446424 | High Doses of Drugs Extensively Metabolized by CYP3A4 Were Needed to Reach Therapeutic Concentrations in Two Patients Taking Inducers. | 2020 Apr - Jun |
1 |
| 3 |
32519344 | CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis. | 2020 Jul |
1 |
| 4 |
21518375 | Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers. | 2012 Apr |
1 |
| 5 |
16321618 | Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. | 2005 Nov |
2 |
| 6 |
11560868 | Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. | 2001 Oct |
2 |
| 7 |
10771452 | Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. | 2000 |
2 |
| 8 |
10048600 | Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. | 1999 Feb |
1 |